A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Ambit Biosciences Corporation
ClinicalTrials.gov Identifier:
NCT01468467
First received: November 7, 2011
Last updated: September 20, 2013
Last verified: September 2013
  Purpose

The purpose of this study is to define a safe dose of AC220 when given as maintenance therapy after treatment with an allogeneic stem cell transplant.


Condition Intervention Phase
Leukemia, Myeloid, Acute,
Drug: AC220
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Study of AC220 (ASP2689) as Maintenance Therapy in Subjects With Acute Myeloid Leukemia Who Have Been Treated With an Allogeneic Hematopoietic Stem Cell Transplant

Resource links provided by NLM:


Further study details as provided by Ambit Biosciences Corporation:

Primary Outcome Measures:
  • Incidence of dose limiting toxicity (DLT) [ Time Frame: up to Day 56 ] [ Designated as safety issue: No ]
    From first dose through last dose of Cycle 2

  • Safety assessed by recording adverse events, physical examinations, vital signs, electrocardiograms (ECGs) and laboratory assessments [ Time Frame: 30 days after last subject discontinues treatment (maximum of 24 months) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Duration of confirmed complete remission (CR) [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Time from first dose until date of relapse

  • Duration of overall complete remission [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Complete remission (CR) + CR with incomplete platelet recovery (CRp) + CR with incomplete hematologic recovery (CRi) + complete molecular remission (CRm)

  • Disease-free survival [ Time Frame: 30 days after last subject discontinues treatment (maximum of 24 months) ] [ Designated as safety issue: No ]
    Time from first dose until date of relapse or death

  • Overall survival [ Time Frame: 30 days after last subject discontinues treatment (maximum of 24 months) ] [ Designated as safety issue: No ]
    Time from first dose until date of death from any cause

  • Percentage of transplant rejections [ Time Frame: 30 days after last subject discontinues treatment (maximum of 24 months) ] [ Designated as safety issue: No ]
    Through End of Treatment

  • Percentage of Subjects with Graft-versus-Host Disease (GVHD) [ Time Frame: Up through 24 months of treatment ] [ Designated as safety issue: No ]
  • Percentage of Donor Chimerism [ Time Frame: Up through 24 months of treatment ] [ Designated as safety issue: No ]
  • Treatment-related mortality (TRM) [ Time Frame: Up through 24 months of treatment ] [ Designated as safety issue: Yes ]
    Death in CR (CR, CRm, CRp and CRi)

  • Composite of pharmacokinetics: AUC24 , Cmax, Ctrough and Tmax [ Time Frame: Up through 24 months of treatment ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: April 2012
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AC220 Drug: AC220
Oral Liquid
Other Names:
  • quizartinib
  • ASP2689

Detailed Description:

This is a two-part, sequential group dose escalation study.

In Part 1, subjects will be enrolled into successive cohorts to determine the maximum tolerated dose (MTD). Dose escalation decision will be made based on dose limiting toxicities (DLTs) that occur in subjects treated to date at a given dose level. In Part 2, a confirmation cohort will be opened to confirm the safety at the MTD.

Subjects who have had an allogeneic Hematopoietic Stem Cell Transplant (HSCT) will enter treatment with AC220 between 30 to 60 days after receiving allogeneic HSCT. AC220 will be administered every day, with 28 consecutive days defined as a treatment cycle. Subjects may receive up to 24 continuous treatment cycles. Subjects will have study visits each week for the first 2 cycles, and then on Day 1 of each cycle after that.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has a diagnosis of acute myeloid leukemia (AML) according to WHO classification (2008) and has received a high dose or a reduced intensity conditioning allogeneic Hematopoietic Stem Cell Transplant (HSCT) during first or second remission and within 30 to 60 days prior to first dose of AC220. Donors may be human leukocyte antigen (HLA)-matched for HLA-A, B, C, DRB1, and DQB1 by high resolution typing, related or unrelated (only a single allele disparity will be allowed for HLA-A, B, or C as defined by high resolution typing) Note: more than one HSCT is allowed
  • Subject must be in morphologic remission (< 5% marrow blasts) and without active central nervous system (CNS) AML within 14 days prior to first dose of AC220
  • Subject must have CD3 donor chimerism > 50 % at Screening
  • Subject has a Karnofsky Performance Status (KPS) of ≥ 60
  • Subject must have absolute neutrophil count (ANC) > 1000/mm3 and platelet count > 50,000/mm3 without platelet transfusion support within 2 weeks prior to first dose
  • Subject must have adequate renal, hepatic, and coagulation parameters
  • Female subjects must not be lactating and must not be breastfeeding at Screening or during the study period and for 28 days [or five half lives of the study drug whichever is longer] after final study drug administration.
  • Subject is able to comply with study procedures and follow-up examinations

Exclusion Criteria:

  • Subject received AC220 and relapsed during treatment with AC220
  • Subject has active ≥ Grade 2 graft versus host disease (GVHD)
  • Subject has received concurrent chemotherapy, immunotherapy, or radio-therapy within 21 days prior to the first dose of AC220, or any antineoplastic therapy that is considered to be investigational (i.e., used for non-approved indications(s) and in the context of a research investigation) within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug
  • Subject requires treatment with concomitant drugs that prolong QT/QTc interval or strong cytochrome P-3A4 (CYP3A4) inhibitors or inducers with the exception of immunosuppressants, antibiotics, antifungals, and antivirals that are used as standard of care post-transplant or to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the subject
  • Subject requires treatment with anticoagulant therapy
  • Subject has a known positive test for human immunodeficiency virus, hepatitis C, or hepatitis B surface antigen
  • Subject had major surgery within 4 weeks prior to first dose of AC220
  • Subject has uncontrolled or significant cardiovascular disease
  • Subject has an active acute fungal, bacterial, or other infection that is unresponsive to therapy
  • Subject has participated in any interventional clinical study or has been treated with any investigational drugs within 30 days or 5 half lives whichever is longer, prior to the initiation of Screening.
  • Subject has any medical, psychiatric, addictive or other kind of disorder which compromises the ability of the subject to give written informed consent and/or to comply with procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01468467

Locations
United States, California
City of Hope
Duarte, California, United States, 91010
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Texas
M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Washington
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Ambit Biosciences Corporation
Investigators
Study Director: Guy Gammon, MB, BS, MRCP Medical Monitor, Ambit Biosciences Corporation
  More Information

No publications provided

Responsible Party: Ambit Biosciences Corporation
ClinicalTrials.gov Identifier: NCT01468467     History of Changes
Other Study ID Numbers: 2689-CL-0011
Study First Received: November 7, 2011
Last Updated: September 20, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Ambit Biosciences Corporation:
AC220
Acute Myeloid Leukemia (AML)
Transplantation
Stem Cell Transplantation
Allogeneic Transplantation
FMS-like tyrosine kinase (FLT3)
FMS-like tyrosine kinase (FLT3) Inhibitor
Kinase
Kinase Inhibitor
Pharmacokinetics
ASP2689
quizartinib

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid, Acute
Leukemia, Myeloid
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on August 21, 2014